Кристи Фанк - Грудь. Руководство пользователя [litres]

M. G. Marmot et al., “The Benefits and Harms of Breast Cancer Screening – An Independent Review: A Report Jointly Commissioned by Cancer Research U. K. and the Department of Health (England) October 2012,” British Journal of Cancer 108, no. 11 (2013): 2205.

K. L. Kummerow et al., “Nationwide Trends in Mastectomy for Early-Stage Breast Cancer,” JAMA Surgery 150 (2015): 9–16; S. T. Hawley et al., “Social and Clinical Determinants of Contralateral Prophylactic Mastectomy,” JAMA Surgery 149 (2014): 582–589.

C. P. McPherson, K. K. Swenson, and M. W. Lee, “The Effects of Mammographic Detection and Comorbidity on the Survival of Older Women with Breast Cancer,” Journal of the American Geriatrics Society 50, no. 6 (2002): 1061–1068.

M. M. Eberl et al., “BI-RADS Classification for Management of Abnormal Mammograms,” The Journal of the American Board of Family Medicine 19, no. 2 (2006): 161–164.

P. A. Carney et al., “Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography,” Annals of Internal Medicine 138 (2003): 168–175.

B. L. Sprague et al., “National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from The Breast Cancer Surveillance Consortium,” Radiology 283, no. 1 (2017): 59–69.

S. H. Taplin et.al., “Reason for Late-Stage Breast Cancer: Absence of Screening or Detection, or Breakdown in Follow-Up?” Journal of the National Cancer Institute 96, no. 20 (October 2004): 1518–1527.

L. Tabar et al., “Mammography Service Screening and Mortality in Breast Cancer Patients: 20-year Follow-Up before and after Introduction of Screening,” The Lancet 361, no. 9367 (2003): 1405–1410.

D. R. Youlden et al., “Incidence and Mortality of Female Breast Cancer in the Asia-Pacific Region,” Cancer Biology and Medicine 11 (2014): 101–115.

R. A. Smith et al., “The Randomized Trials of Breast Cancer Screening: What Have We Learned?” Radiologic Clinics of North America 42, no. 5 (2004): 793–806; M. Broeders et al., “The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies,” Journal of Medical Screening 19, no. 1 (2012): 14–25; Preventive Services Task Force, “Screening for Breast Cancer: Recommendations and Rationale,” Annals of Internal Medicine 137 (2002): 344–346; D. A. Berry, “Benefits and Risks of Screening Mammography for Women in their Forties: A Statistical Appraisal,” Journal of the National Cancer Institute 90 (1998): 1431–1439.

E. D. Pisano et al., “Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening,” New England Journal of Medicine 353, no. 17 (October 2005): 1773–1783.

S. Ciatto et al., “Integration of 3D Digital Mammography with Tomosynthesis for Population Breast-Cancer Screening (STORM): A Prospective Comparison Study,” The Lancet Oncology 14 (2013): 583–589.

A. S. Tagliafico et al., “Diagnostic Performance of Contrast-Enhanced Spectral Mammography: Systematic Review and Meta-analysis,” The Breast 28 (2016): 13–19.

E. M. Fallenberg et al., “Contrast-Enhanced Spectral Mammography versus MRI: Initial Results in the Detection of Breast Cancer and Assessment of Tumour Size,” European Radiology 24, no. 1 (2014): 256–264.

P. A. Carney et al., “Factors Associated with Imaging and Procedural Events Used to Detect Breast Cancer after Screening Mammography,” American Journal of Roentgenology 188, no. 2 (2007): 385–392.

J. G. Elmore et al., “Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations,” New England Journal of Medicine 338, no. 16 (April 1998): 1089–1096.

S. Törnberg et al., “A Pooled Analysis of Interval Cancer Rates in Six European Countries,” European Journal of Cancer Prevention 19, no. 2 (2010): 87–93.

P. A. Carney et al., “Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography,” Annals of Internal Medicine 138, no. 3 (2003): 168–175; T. M. Kolb, J. Lichy, and J. H. Newhouse, “Comparison of the Performance of Screening Mammography, Physical Examination, and Breast US and Evaluation of Factors that Influence Them: An Analysis of 27,825 Patient Evaluations,” Radiology 225, no. 1 (2002): 165–175.

S. S. K. Tang and G. P. H. Gui, “A Review of the Oncologic and Surgical Management of Breast Cancer in the Augmented Breast: Diagnostic, Surgical and Surveillance Challenges,” Annals of Surgical Oncology 18, no. 8 (2011): 2173–2181.

M. J. Yaffe and J. G. Mainprize, “Risk of Radiation-Induced Breast Cancer from Mammographic Screening 1,” Radiology 258, no. 1 (2011): 98–105.

L. M. Warren, D. R. Dance, and K. C. Young, “Radiation Risk of Breast Screening in England with Digital Mammography,” British Journal of Radiology 89 (November 2016): 1067; D. L. Miglioretti et al., “Radiation-Induced Breast Cancer Incidence and Mortality from Digital Mammography Screening: A Modeling Study,” Annals of Internal Medicine 164, no. 4 (2016): 205–214.

“Patient Safety: Radiation Dose in X-Ray and CT Exams,” RadiologyInfo.org, обновлено 8 февраля 2017 года, https://www.radiologyinfo.org/en/info.cfm?pg=safety-xray.

“Patient Safety: Radiation Dose in X-Ray and CT Exams,” RadiologyInfo.org, обновлено 8 февраля 2017 года, https://www.radiologyinfo.org/en/info.cfm?pg=safety-xray.

C. H. C. Drossaert, H. Boer, and E. R. Seydel, “Monitoring Women’s Experiences During Three Rounds of Breast Cancer Screening: Results from a Longitudinal Study,” Journal of Medical Screening 9, no. 4 (2002): 168–175.

US Preventive Services Task Force, “Screening for Breast Cancer: U. S. Preventive Services Task Force Recommendation Statement,” Annals of Internal Medicine 151, no. 10 (2009): 716.

L. M. Schwartz et al., “US Women’s Attitudes to False Positive Mammography Results and Detection of Ductal Carcinoma in Situ: Cross Sectional Survey,” British Medical Journal 320, no. 7250 (2000): 1635–1640.

E. K. Arleo et al., “Comparison of Recommendations for Screening Mammography Using CISNET Models,” Cancer 123, no. 19 (October 2017): 3673–3680.

В России рекомендованные сроки прохождения маммографии отличаются.

A. S. Tagliafico et al., “Adjunct Screening with Tomosynthesis or Ultrasound in Women with Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial,” Journal of Clinical Oncology 34, no. 16 (2016): 1882–1888.

F. Sardanelli et al., “Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study): Final Results,” Investigative Radiology 46, no. 2 (2011): 94–105.

M. E. Brennan et al., “Magnetic Resonance Imaging Screening of the Contralateral Breast in Women with Newly Diagnosed Breast Cancer: Systematic Review and Meta-analysis of Incremental Cancer Detection and Impact on Surgical Management,” Journal of Clinical Oncology 27, no. 33 (2009): 5640–5649.

M. Kriege et al., “Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition,” New England Journal of Medicine 351, no. 5 (2004): 427–437.

C. D. Lehman, “Clinical Indications: What Is the Evidence?” European Journal of Radiology 81 (2012): S82–S84.

N. Houssami, R. Turner, and M. Morrow, “Preoperative Magnetic Resonance Imaging in Breast Cancer: Meta-analysis of Surgical Outcomes,” Annals of Surgery 257, no. 2 (2013): 249–255. 40. M. Morrow, J. Waters, and E. Morris, “MRI for Breast Cancer Screening, Diagnosis, and Treatment,” Lancet 378, no. 9805 (2011): 1804–1811.

National Comprehensive Cancer Network, “Guidelines for Breast Cancer Screening and Diagnosis,” http://www.NCCN.org.

C. C. Riedl et al., “Triple-Modality Screening Trial for Familial Breast Cancer Underlines the Importance of Magnetic Resonance Imaging and Questions the Role of Mammography and Ultrasound Regardless of Patient Mutation Status, Age, and Breast Density,” Journal of Clinical Oncology 33, no. 10 (2015): 1128–1135.

E. M. Fallenberg et al., “Contrast-Enhanced Spectral Mammography versus MRI: Initial Results in the Detection of Breast Cancer and Assessment of Tumour Size,” European Radiology 24, no. 1 (2014): 256–264.

U. S. Food and Drug Administration, “FDA Drug Safety Communication: FDA Evaluating the Risk of Brain Deposits with Repeated Use of Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (MRI),” FDA.gov, открыто 27 августа 2017 года, http://www.fda.gov/Drugs/DrugSafety/ucm455386.htm.

J. Hermans, “The Value of Aspiration Cytologic Examination of the Breast: A Statistical Review of the Medical Literature,” Cancer 69, no. 8 (April 1992): 2104–2110; F. O’Malley et al., “Clinical Correlates of False-Negative Fine Needle Aspirations of The Breast in a Consecutive Series of 1,005 Patients,” Surgery, Gynecology and Obstetrics 176, no. 4 (April 1993): 360–364; N. J. Wollenberg et al., “Fine Needle Aspiration Cytology of the Breast: A Review of 321 Cases with Statistical Evaluation,” Acta Cytologica 29 (1985): 425–429.

P. Crystal et al., “Accuracy of Sonographically Guided 14-Gauge Core-Needle Biopsy: Results of 715 Consecutive Breast Biopsies with at Least Two-Year Follow-Up of Benign Lesions,” Journal of Clinical Ultrasound 33, no. 2 (February 2005): 47–52; M. Memarsadeghi et al., “Value of 14-Gauge Ultrasound-Guided Large-Core Needle Biopsy of Breast Lesions: Own Results in Comparison with the Literature,” RoFo 175, no. 3 (March 2003): 374–380; J. M. Schoonjans and R. F. Brem, “Fourteen-Gauge Ultrasonographically Guided Large-Core Needle Biopsy of Breast Masses,” Journal of Ultrasound in Medicine 20, no. 9 (September 2001): 967–972; D. N. Smith et al., “The Utility of Ultrasonographically Guided Large-Core Needle Biopsy: Results from 500 Consecutive Breast Biopsies,” Journal of Ultrasound in Medicine 20, no. 1 (January 2001): 43–49.